The Impact of Serum Uric Acid on Postoperative Atrial Fibrillation in Coronary Artery Bypass Graft
Keywords:Uric acid, Postoperative atrial fibrillation, coronary artery bypass
Background: Postoperative atrial fibrillation (POAF) after cardiac surgery is a common complication. We aimed to investigate the impact of serum uric acid level (UA) on the POAF of patients undergoing coronary artery bypass grafting (CABG).
Methods: A retrospective cohort study of patients undergoing CABG at the Hospital between January 2019 and December 2019 was performed. Hyperuricemia (HUA) was defined as serum UA levels >420 µmol/l in men and>360 µmol/l in women. The included patients were divided into the HUA group (103) and the normal UA group (306) based on serum uric acid levels before surgery. POAF was defined as atrial fibrillation that occurred within 7 days of cardiac surgery. We use COX regression analysis and Kaplan-Meier curves (log-rank test) for statistical analysis.
Results: The incidence of HUA was 25.2% (103/409). The rate of POAF was 28.61%. Univariate COX regression analysis showed the risk of POAF occurrence. It was revealed that UA was an independent predictor of POAF (HR=1.493, 95% CI1.007-2.212, P = 0.046). Kaplan-Meier curves showed that high serum UA was associated with the occurrence of POAF (P = 0.034). Moreover, age (HR=1.05, 95%CI 1.024-1.076, P < 0.001), AD (HR=1.567, 95%CI .015-2.42, P = 0.043), and CCB (HR=0.647, 95%CI 0.424-0.988, P = 0.044) also were independent predictors of POAF.
Conclusions: Preoperative UA level was significantly associated with POAF. Higher serum UA was an independent risk factor for POAF.
Alem MM. 2018.Allopurinol and endothelial function: A systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther. Aug 36(4):e12432.
Benedetto U, Gaudino MF, Dimagli A, et al. 2020. Postoperative Atrial Fibrillation and Long-Term Risk of Stroke After Isolated Coronary Artery Bypass Graft Surgery. Circulation. Oct 6. 142(14):1320-1329.
Chen CC, Hsu YJ, Lee TM. 2011. Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia. Am J Physiol Heart Circ Physiol. Sep 301(3):H1107-17.
Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. 2008. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. Feb 26(2):269-75.
Deng Y, Liu F, Yang X, Xia Y. 2021. The Key Role of Uric Acid in Oxidative Stress, Inflammation, Fibrosis, Apoptosis, and Immunity in the Pathogenesis of Atrial Fibrillation. Front Cardiovasc Med. 8:641136.
Echahidi N, Pibarot P, O'Hara G, Mathieu P. 2008. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J Am Coll Cardiol. Feb 26 51(8):793-801.
Gaubert M, Bardin T, Cohen-Solal A, et al. 2020. Hyperuricemia and Hypertension, Coronary Artery Disease, Kidney Disease: From Concept to Practice. Int J Mol Sci. Jun 6 21(11).
Harada M, Van Wagoner DR, Nattel S. 2015. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J. 79(3):495-502.
Hong M, Park JW, Yang PS, et al. 2020. A mendelian randomization analysis: The causal association between serum uric acid and atrial fibrillation. Eur J Clin Invest. Oct 50(10):e13300.
Ishii Y, Schuessler RB, Gaynor SL, et al. 2005. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation. Jun 7 111(22):2881-8.
Ishii Y, Schuessler RB, Gaynor SL, Hames K, Damiano RJ, Jr. 2017. Postoperative atrial fibrillation: The role of the inflammatory response. J Thorac Cardiovasc Surg. Jun 153(6):1357-1365.
Kang DH, Chen W. 2011. Uric acid and chronic kidney disease: new understanding of an old problem. Semin Nephrol. Sep 31(5):447-52.
Kawasoe S, Kubozono T, Yoshifuku S, et al. 2018. Uric Acid Level and New-Onset Atrial Fibrillation in the Japanese General Population- Longitudinal Study. Circ J. Dec 25 83(1):156-163.
Kurajoh M, Fukumoto S, Yoshida S, et al. 2021. Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry. Sci Rep-Uk. Apr 1 11(1).
Kwon CH, Lee SH, Lee JY, Ryu S, Sung KC. 2018. Uric Acid and Risk of Atrial Fibrillation in the Korean General Population. Circ J. Oct 25 82(11):2728-2735.
Lee TM, Lin SZ, Chang NC. 2016. Effects of urate-lowering agents on arrhythmia vulnerability in post-infarcted rat hearts. J Pharmacol Sci. May 131(1):28-36.
Li J, Solus J, Chen QX, et al. 2010. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. Apr 7(4):438-444.
Liu CW, Ke SR, Tseng GS, Wu YW, Hwang JJ. 2021. Elevated serum uric acid is associated with incident hypertension in the health according to various contemporary blood pressure guidelines. Nutr Metab Cardiovasc Dis. Apr 9 31(4):1209-1218.
Maharani N, Kuwabara M, Hisatome I. 2016. Hyperuricemia and Atrial Fibrillation. Int Heart J. Jul 27 57(4):395-9.
Mathew JP, Fontes ML, Tudor IC, et al. 2004. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. Apr 14 291(14):1720-9.
Memetoglu ME, Kehlibar T, Yilmaz M, et al. 2015. Serum uric acid level predicts new-onset atrial fibrillation after coronary artery bypass graft operation. Eur Rev Med Pharmaco. Mar 19(5):784-789.
Nan H, Qiao Q, Dong Y, et al. 2006. The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol. Jul 33(7):1346-50.
Perlstein TS, Gumieniak O, Hopkins PN, et al. 2004. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int. Oct 66(4):1465-70.
Saito Y, Tanaka A, Node K, Kobayashi Y. 2021. Uric acid and cardiovascular disease: A clinical review. J Cardiol. Jul 78(1):51-57.
Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE. 2012. Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J Cardiol. Jan 15 109(2):219-25.
Shen J, Lall S, Zheng V, Buckley P, Damiano RJ, Jr., Schuessler RB. 2011. The persistent problem of new-onset postoperative atrial fibrillation: a single-institution experience over two decades. J Thorac Cardiovasc Surg. Feb 141(2):559-70.
Spiga R, Marini MA, Mancuso E, et al. 2017. Uric Acid Is Associated With Inflammatory Biomarkers and Induces Inflammation Via Activating the NF-kappaB Signaling Pathway in HepG2 Cells. Arterioscler Thromb Vasc Biol. Jun 37(6):1241-1249.
Taha A, Nielsen SJ, Bergfeldt L, et al. 2021. New-Onset Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Outcome: A Population-Based Nationwide Study From the SWEDEHEART Registry. J Am Heart Assoc. Jan 5 10(1):e017966.
Tamariz L, Hernandez F, Bush A, Palacio A, Hare JM. 2014. Association between serum uric acid and atrial fibrillation: a systematic review and meta-analysis. Heart Rhythm. Jul 11(7):1102-8.
Thoren E, Wernroth ML, Christersson C, Grinnemo KH, Jideus L, Stahle E. 2020. Compared with matched controls, patients with postoperative atrial fibrillation (POAF) have increased long-term AF after CABG, and POAF is further associated with increased ischemic stroke, heart failure and mortality even after adjustment for AF. Clin Res Cardiol. Oct 109(10):1232-1242.
Wang D, Sun L, Zhang G, et al. 2021. Increased Susceptibility of Atrial Fibrillation Induced by Hyperuricemia in Rats: Mechanisms and Implications. Cardiovasc Toxicol. Mar 21(3):192-205.
Wang Y, Weng P, Wan H, et al. 2020. Economic Status Moderates the Association Between Early-Life Famine Exposure and Hyperuricemia in Adulthood. J Clin Endocrinol Metab. Nov 1 105(11).
Woldendorp K, Farag J, Khadra S, Black D, Robinson B, Bannon P. 2020. Postoperative atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg. Dec 16.
Yang Y, Zhao J, Qiu J, et al. 2018. Xanthine Oxidase Inhibitor Allopurinol Prevents Oxidative Stress-Mediated Atrial Remodeling in Alloxan-Induced Diabetes Mellitus Rabbits. J Am Heart Assoc. May 2 7(10).
Yu W, Cheng JD. 2020. Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective. Front Pharmacol. 11:582680.
Zhang YS, Lu LQ, Jiang YQ, et al. 2021. Allopurinol attenuates oxidative injury in rat hearts suffered ischemia/reperfusion via suppressing the xanthine oxidase/vascular peroxidase 1 pathway. Eur J Pharmacol. Jul 22 908:174368.
Zhao J, Liu T, Korantzopoulos P, et al. 2016. Association between serum uric acid and atrial fibrillation recurrence following catheter ablation: A meta-analysis. Int J Cardiol. Feb 1 204:103-5.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).